These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 32173511)

  • 1. Disease Burden and Long-Term Risk of Persistent Very Poorly Controlled Asthma: TENOR II.
    Haselkorn T; Szefler SJ; Chipps BE; Bleecker ER; Harkins MS; Paknis B; Kianifard F; Ortiz B; Zeiger RS
    J Allergy Clin Immunol Pract; 2020; 8(7):2243-2253. PubMed ID: 32173511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More than a decade follow-up in patients with severe or difficult-to-treat asthma: The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) II.
    Chipps BE; Haselkorn T; Paknis B; Ortiz B; Bleecker ER; Kianifard F; Foreman AJ; Szefler SJ; Zeiger RS;
    J Allergy Clin Immunol; 2018 May; 141(5):1590-1597.e9. PubMed ID: 28797732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study.
    Haselkorn T; Fish JE; Zeiger RS; Szefler SJ; Miller DP; Chipps BE; Simons FE; Weiss ST; Wenzel SE; Borish L; Bleecker ER;
    J Allergy Clin Immunol; 2009 Nov; 124(5):895-902.e1-4. PubMed ID: 19811812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma.
    Dolan CM; Fraher KE; Bleecker ER; Borish L; Chipps B; Hayden ML; Weiss S; Zheng B; Johnson C; Wenzel S;
    Ann Allergy Asthma Immunol; 2004 Jan; 92(1):32-9. PubMed ID: 14756462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Key findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study.
    Chipps BE; Zeiger RS; Borish L; Wenzel SE; Yegin A; Hayden ML; Miller DP; Bleecker ER; Simons FE; Szefler SJ; Weiss ST; Haselkorn T;
    J Allergy Clin Immunol; 2012 Aug; 130(2):332-42.e10. PubMed ID: 22694932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic burden of impairment in children with severe or difficult-to-treat asthma.
    Szefler SJ; Zeiger RS; Haselkorn T; Mink DR; Kamath TV; Fish JE; Chipps BE
    Ann Allergy Asthma Immunol; 2011 Aug; 107(2):110-119.e1. PubMed ID: 21802018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allergy, total serum immunoglobulin E, and airflow in children and adolescents in TENOR.
    Haselkorn T; Szefler SJ; Simons FE; Zeiger RS; Mink DR; Chipps BE; Borish L; Wong DA;
    Pediatr Allergy Immunol; 2010 Dec; 21(8):1157-65. PubMed ID: 20444153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asthma in older adults: observations from the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) study.
    Slavin RG; Haselkorn T; Lee JH; Zheng B; Deniz Y; Wenzel SE;
    Ann Allergy Asthma Immunol; 2006 Mar; 96(3):406-14. PubMed ID: 16597074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical burden and predictors of asthma exacerbations in patients on guideline-based steps 4-6 asthma therapy in the TENOR cohort.
    Calhoun WJ; Haselkorn T; Mink DR; Miller DP; Dorenbaum A; Zeiger RS
    J Allergy Clin Immunol Pract; 2014; 2(2):193-200. PubMed ID: 24607048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TENOR risk score predicts healthcare in adults with severe or difficult-to-treat asthma.
    Miller MK; Lee JH; Blanc PD; Pasta DJ; Gujrathi S; Barron H; Wenzel SE; Weiss ST;
    Eur Respir J; 2006 Dec; 28(6):1145-55. PubMed ID: 16870656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study.
    Lee JH; Haselkorn T; Borish L; Rasouliyan L; Chipps BE; Wenzel SE
    Chest; 2007 Dec; 132(6):1882-9. PubMed ID: 18079222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Very Poorly Controlled Asthma in Urban Minority Children: Lessons Learned.
    Butz AM; Bellin M; Tsoukleris M; Mudd SS; Kub J; Ogborn J; Morphew T; Lewis-Land C; Bollinger ME
    J Allergy Clin Immunol Pract; 2018; 6(3):844-852. PubMed ID: 28958744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma.
    Mascia K; Haselkorn T; Deniz YM; Miller DP; Bleecker ER; Borish L;
    J Allergy Clin Immunol; 2005 Nov; 116(5):970-5. PubMed ID: 16275362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-life retrospective observational study to determine the prevalence and economic burden of severe asthma in Spain.
    Sicras-Mainar A; Capel M; Navarro-Artieda R; Nuevo J; Orellana M; Resler G
    J Med Econ; 2020 May; 23(5):492-500. PubMed ID: 31958257
    [No Abstract]   [Full Text] [Related]  

  • 15. Gender differences in IgE-mediated allergic asthma in the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study.
    Lee JH; Haselkorn T; Chipps BE; Miller DP; Wenzel SE;
    J Asthma; 2006 Apr; 43(3):179-84. PubMed ID: 16754518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Asthma Impairment and Risk Questionnaire (AIRQ) Control Level Predicts Future Risk of Asthma Exacerbations.
    Beuther DA; Murphy KR; Zeiger RS; Wise RA; McCann W; Reibman J; George M; Gilbert I; Eudicone JM; Gandhi HN; Ross M; Coyne KS; Chipps B
    J Allergy Clin Immunol Pract; 2022 Dec; 10(12):3204-3212.e2. PubMed ID: 35998877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asthma Exacerbations and Triggers in Children in TENOR: Impact on Quality of Life.
    Chipps BE; Haselkorn T; Rosén K; Mink DR; Trzaskoma BL; Luskin AT
    J Allergy Clin Immunol Pract; 2018; 6(1):169-176.e2. PubMed ID: 28803186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prevalence and disease burden of severe eosinophilic asthma in Japan.
    Nagasaki T; Sato K; Kume N; Oguma T; Sunadome H; Ito I; Izuhara Y; Okamoto K; Kobayashi S; Ohno T; Mizukami A; Kobayashi A; Kaise T; Kuroda T; Mishima M; Matsumoto H
    J Asthma; 2019 Nov; 56(11):1147-1158. PubMed ID: 30822174
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
    Lee LA; Bailes Z; Barnes N; Boulet LP; Edwards D; Fowler A; Hanania NA; Kerstjens HAM; Kerwin E; Nathan R; Oppenheimer J; Papi A; Pascoe S; Brusselle G; Peachey G; Sule N; Tabberer M; Pavord ID
    Lancet Respir Med; 2021 Jan; 9(1):69-84. PubMed ID: 32918892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predominance of Atopic Asthma in Patients with Severe or Difficult-to-Treat Asthma in the TENOR-II cohort.
    Haselkorn T; Mink D; Kianifard F; Ortiz B; Paknis B; Lecocq J; Chipps BE; Bleecker ER
    Ann Allergy Asthma Immunol; 2021 Nov; 127(5):593-595. PubMed ID: 34391902
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.